BACKGROUND: We report composite results from the Merck phase I program of near-consensus clade B human immunodeficiency virus (HIV) type 1 gag vaccines. METHODS:Healthy HIV-uninfected adults were enrolled in 6 blinded placebo-controlled studies evaluating the immunogenicity of (1) a 4-dose regimen of a DNA vaccine, (2) a 3-dose priming regimen of the DNA vaccine with a booster dose of an adenovirus type 5 (Ad5)-vectored vaccine, or (3) a 3-dose regimen of the Ad5 vaccine. The DNA plasmid was provided with or without an aluminum phosphate or CRL1005 adjuvant. The primary end point was the unfractionated HIV-1 gag-specific interferon gamma enzyme-linked immunospot (ELISpot) response 4 weeks after the final dose. RESULTS: Overall, 254 (83%) of 307 subjects randomized to the vaccine groups were evaluable. Adjuvants did not enhance immunogenicity of the DNA vaccine. Postboost ELISpot responder frequencies were higher for Ad5-containing regimens than for the DNA/DNA regimen (33%) but were similar for DNA/Ad5 (55%) and Ad5/Ad5 (50%). DNA/DNA elicited mainly a CD4 response, whereas Ad5/Ad5 elicited mainly a CD8 response; DNA/Ad5 generated CD4 and CD8 responses comparable to those of DNA/DNA and Ad5/Ad5, respectively. CONCLUSIONS: The DNA vaccine alone or as a priming regimen for the Ad5 vaccine did not increase unfractionated ELISpot responses compared with the Ad5 vaccine alone. Qualitative T cell responses to different vaccine regimens deserve further study.
RCT Entities:
BACKGROUND: We report composite results from the Merck phase I program of near-consensus clade B human immunodeficiency virus (HIV) type 1 gag vaccines. METHODS: Healthy HIV-uninfected adults were enrolled in 6 blinded placebo-controlled studies evaluating the immunogenicity of (1) a 4-dose regimen of a DNA vaccine, (2) a 3-dose priming regimen of the DNA vaccine with a booster dose of an adenovirus type 5 (Ad5)-vectored vaccine, or (3) a 3-dose regimen of the Ad5 vaccine. The DNA plasmid was provided with or without an aluminum phosphate or CRL1005 adjuvant. The primary end point was the unfractionated HIV-1 gag-specific interferon gamma enzyme-linked immunospot (ELISpot) response 4 weeks after the final dose. RESULTS: Overall, 254 (83%) of 307 subjects randomized to the vaccine groups were evaluable. Adjuvants did not enhance immunogenicity of the DNA vaccine. Postboost ELISpot responder frequencies were higher for Ad5-containing regimens than for the DNA/DNA regimen (33%) but were similar for DNA/Ad5 (55%) and Ad5/Ad5 (50%). DNA/DNA elicited mainly a CD4 response, whereas Ad5/Ad5 elicited mainly a CD8 response; DNA/Ad5 generated CD4 and CD8 responses comparable to those of DNA/DNA and Ad5/Ad5, respectively. CONCLUSIONS: The DNA vaccine alone or as a priming regimen for the Ad5 vaccine did not increase unfractionated ELISpot responses compared with the Ad5 vaccine alone. Qualitative T cell responses to different vaccine regimens deserve further study.
Authors: Sergey S Seregin; Yasser A Aldhamen; David P W Rastall; Sarah Godbehere; Andrea Amalfitano Journal: Vaccine Date: 2011-12-23 Impact factor: 3.641
Authors: Erica A Mendes; Bráulia C Caetano; Marcus L O Penido; Oscar Bruna-Romero; Ricardo T Gazzinelli Journal: Vaccine Date: 2011-05-05 Impact factor: 3.641
Authors: Thomas W Geisbert; Michael Bailey; Lisa Hensley; Clement Asiedu; Joan Geisbert; Daphne Stanley; Anna Honko; Joshua Johnson; Sabue Mulangu; Maria Grazia Pau; Jerome Custers; Jort Vellinga; Jenny Hendriks; Peter Jahrling; Mario Roederer; Jaap Goudsmit; Richard Koup; Nancy J Sullivan Journal: J Virol Date: 2011-02-16 Impact factor: 5.103
Authors: Clint S Schmidt; C Jo White; Ashraf S Ibrahim; Scott G Filler; Yue Fu; Michael R Yeaman; John E Edwards; John P Hennessey Journal: Vaccine Date: 2012-10-22 Impact factor: 3.641
Authors: Thorsten Demberg; Egidio Brocca-Cofano; Seraphin Kuate; Stanley Aladi; Diego A Vargas-Inchaustegui; David Venzon; Irene Kalisz; V S Kalyanaraman; Eun Mi Lee; Ranajit Pal; Janet DiPasquale; Ruth M Ruprecht; David C Montefiori; Indresh Srivastava; Susan W Barnett; Marjorie Robert-Guroff Journal: Virology Date: 2013-03-22 Impact factor: 3.616
Authors: Richard A Koup; Mario Roederer; Laurie Lamoreaux; Jennifer Fischer; Laura Novik; Martha C Nason; Brenda D Larkin; Mary E Enama; Julie E Ledgerwood; Robert T Bailer; John R Mascola; Gary J Nabel; Barney S Graham Journal: PLoS One Date: 2010-02-02 Impact factor: 3.240
Authors: Robert J O'Connell; Jerome H Kim; Lawrence Corey; Nelson L Michael Journal: Cold Spring Harb Perspect Med Date: 2012-12-01 Impact factor: 6.915
Authors: Peter Hayes; Jill Gilmour; Andrea von Lieven; Dilbinder Gill; Lorna Clark; Jakub Kopycinski; Hannah Cheeseman; Amy Chung; Galit Alter; Len Dally; Devika Zachariah; Angela Lombardo; James Ackland; Eddy Sayeed; Akil Jackson; Marta Boffito; Brian Gazzard; Patricia E Fast; Josephine H Cox; Dagna Laufer Journal: Clin Vaccine Immunol Date: 2013-01-23